YMAB250117P5000
- 0.00
- 0.000.00%
Y-mAbs Therapeutics Newsroom
BofA Securities Maintains Y-mAbs Therapeutics(YMAB.US) With Hold Rating, Maintains Target Price $14
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
JonesTrading Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)
Express News | Y-mAbs Therapeutics - Expects Restructuring Expenses of up to $2.6 Mln
Express News | Y-mAbs Appoints Experienced Commercial Leader as Head of Danyelza Business Unit
Y-mAbs Reports Preliminary Estimated 2024 Total Net Revenue Of $88M, Within $87M - $91M Prior Guidance Range; Est $88.221M
Express News | Y-mAbs Therapeutics: Intends to Move Some Roles From Denmark to U.S.
Y-Mabs Therapeutics Said It Is Internally Realigning Operations With The Establishment Of Two Business Units: Radiopharmaceuticals And Danyelza And Announced 2025 Priorities
Express News | Y-mAbs Therapeutics Inc - to Dose First Nhl Patient in Study 1201 in Q1 2025
Express News | Y-mAbs Therapeutics Inc - Anticipates Workforce Reduction of up to 13%
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Express News | Y-mAbs Therapeutics Inc : BofA Global Research Cuts Price Objective to $14 From $17
BofA Securities Maintains Y-mAbs Therapeutics(YMAB.US) With Hold Rating, Cuts Target Price to $14
Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) Have Lost 74%, as Stock Drops 14% This Past Week
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely
Clear Street Launches Healthcare & Biotechnology Equity Research
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics